Menu
Skip to content

Magnetic Resonance Spectroscopy (MRS)

MR spectroscopy addresses the non-invasive detection of small molecules in the organism (e.g. N-acetylaspartate, choline, lactate, phosphocreatine). Analyses of the in-vivo concentrations of such metabolites in body tissue are mainly performed at the 3T-high-field MRI with proton(1H)- and phosphorus(31P)-MRS. MRS is scientifically applied for the following diseases: Neurodegenerative diseases (e.g. neurodegenerative diseases (e.g. amyotrophic lateral sclerosis, including motor neuron diseases, Alzheimer's disease), neuro-inflammatory diseases (e.g. multiple sclerosis, leukodystrophy), schizophrenia and brain tumours. The MRS is also used as in-vivo gold standard in MR-relaxometry as well as for the determination of the proton density fat fraction.

PD Dr. rer. nat. Wolfgang Block

Tel.: +49 228 287 - 11835
E-Mail: Enable JavaScript to view protected content.

 

PD Dr.-Ing. Alois Martin Sprinkart

Tel.: +49 228 287 11833
E-Mail: Enable JavaScript to view protected content.
CV

 

Unsere Webseite verwendet Cookies.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Unsere Webseite verwendet Cookies.

These include essential cookies that are necessary for the operation of the site, as well as others that are used only for anonymous statistical purposes, for comfort settings or to display personalized content. You can decide for yourself which categories you want to allow. Please note that based on your settings, not all functions of the website may be available.

Your cookie preferences have been saved.

Information gemäß § 6 Medizinprodukte-Betreiberverordnung "Beauftragter für Medizinproduktesicherheit"

Sehr geehrte Damen und Herren,

gemäß § 6 Medizinprodukte-Betreiberverordnung steht Ihnen das Universitätsklinikum Bonn im Zusammenhang mit Meldungen über Risiken von Medizinprodukten, Informationen zu Rückrufen oder Warn- und Sicherheitshinweisen sowie bei der Umsetzung von notwendigen korrektiven Maßnahmen unter folgender E-Mailadresse zur Verfügung: Enable JavaScript to view protected content.

Diese E-Mailadresse richtet sich vorzugsweise an Kontaktpersonen von Behörden, Herstellern und Vertreibern von Medizinprodukten.